SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
SELLAS Life Sciences Group Inc (NASDAQ:SLS) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co's (NYSE:BMY) nivolumab (Opdivo) in with malignant pleural mesothelioma (MPM). The trial included patients who were either refractory or relapsed after at least one line of the standard of care therapy. Data from…
Benzinga ·